Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

This article is part of the supplement: 24th European Workshop for Rheumatology Research

Meeting abstract

Multiplex analysis of antinuclear antibodies by flow cytometry using FIDIS

PJ Charles

Division of Immunology, Hammersmith Hospitals NHS Trust and Kennedy Division, Imperial College, London, UK

from 24th European Workshop for Rheumatology Research
Berlin, Germany. 26–29 February 2004

Arthritis Res Ther 2004, 6(Suppl 1):8doi:10.1186/ar1050

Received: 16 January 2004
Published: 24 February 2004

Background

FIDIS (BMD, France) is a multiplex analytical flow cytometry system for the detection of antibodies. The aim of this study was to evaluate the FIDIS connective assay system for the detection of antinuclear antibodies (ANA), and to assess the clinical utility of these parameters in the diagnosis of connective tissue diseases. The FIDIS system simultaneously measures IgG antibodies directed at dsDNA, Ro, La, RNP, Sm, Jo-1, Scl-70, rRNP, and CENP-B.

Methods

Sera were obtained from 100 patients with SLE and 100 patients with Sjögren's syndrome. A total of 78 sera from patients with rheumatoid arthritis (RA) and 100 from normal healthy blood donors were also tested.

Results

Antibodies to Scl-70, Jo-1, and rRNP were not detected in any of the sera from the disease groups. In the normal control group, the only positive result obtained was in one sera that gave a weak positive result for anti-CENP-B.

Conclusion

The FIDIS connective assay system simultaneously measures IgG antibodies directed against nine different specificities. The data presented indicate that this system provides an alternative strategy for the measurement of specific ANA to the use of multiple single analyte assays currently employed in many immunology laboratories.

Table 1. Frequency of antibodies detected using FIDIS™

Have something to say? Post a comment on this article!


© 1999-2008 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.